ライフサイエンスコーパス: PPAR-alpha

1 ad been deleted by homologous recombination (PPAR-alpha(-/-)).

2 isome proliferator-activated receptor alpha (PPAR alpha).

3 isome proliferator-activated receptor-alpha (PPAR-alpha).

4 some proliferators activated receptor-alpha (PPAR-alpha).

5 isome proliferator-activated receptor alpha (PPAR-alpha).

6 isome proliferator-activated receptor alpha (PPAR-alpha).

7 l M2 genes (IL-13, SPHK1, CD163, LYVE-1, and PPAR-alpha).

8 me peptides on PPAR delta and in one case on PPAR alpha.

9 iferation, but not in the genetic absence of PPAR alpha.

10 lta-subtype can compensate for deficiency of PPAR alpha.

11 gonists and abolished in mutant mice lacking PPAR-alpha.

12 s the activation of microglia independent of PPAR-alpha.

13 e from a Th1 to a Th2 profile independent of PPAR-alpha.

14 sses the activity of PPAR-gamma (PPAR-g) and PPAR-alpha.

15 mice but has no effect in mice deficient in PPAR-alpha.

16 which also were dependent on the presence of PPAR-alpha.

17 e its analog OEA, as an endogenous ligand of PPAR-alpha.

18 re that, in the liver, TRB-3 is a target for PPAR-alpha.

19 wild-type mice, but not in mice deficient in PPAR-alpha.

20 re stimulated by pharmacologic activation of PPAR-alpha.

21 alpha, the dominant-negative mutant of human PPAR-alpha.

22 hat gemfibrozil inhibits iNOS independent of PPAR-alpha.

23 cts of 15D-PGJ2 may include 1) activation of PPAR-alpha, 2) activation of PPAR-gamma, 3) expression o

24 isome proliferator activated receptor alpha (PPAR-alpha)(3), and lowered PPAR-alpha activity increase

25 isome proliferator-activated receptor alpha (PPAR alpha), a member of the nuclear receptor family.

26 isome proliferator-activated receptor alpha (PPAR-alpha), a fatty acid binding transcription factor t

27 isome-proliferator-activated receptor-alpha (PPAR-alpha), a nuclear receptor that regulates several a

28 creases the activity of the nuclear receptor PPAR-alpha, a PGC-1alpha binding partner, to promote fat

29 n insulin sensitivity, and direct effects of PPAR-alpha action on the islet itself.

30 is study demonstrates that the activation of PPAR-alpha action via fenofibrate leads to neuroprotecti

31 h LDL(-) alone, LPL-treated LDL(-) increased PPAR alpha activation 20-fold in either cell-based trans

32 These findings suggest LPL-mediated PPAR alpha activation as an alternative catabolic pathwa

33 Although human plasma possesses minimal PPAR alpha activation despite containing abundant free f

34 containing abundant free fatty acids, marked PPAR alpha activation is seen with human plasma after LP

35 The PPAR alpha activation seen with LDL, however, was dispro

36 These findings suggest PPAR-alpha activation as a hepatoprotective adaptive res

37 PPAR-alpha activation in the enterocyte on HDL and chylo

38 PPAR-alpha activation in vivo led to increased insulin s

39 lipids, the pharmacological consequences of PPAR-alpha activation on cardiac metabolism and function

40 We studied the impact of PPAR-alpha activation on emotional behavior in a mouse m

41 expressed genes between PPAR-beta/delta and PPAR-alpha activation revealed distinct profiles.

42 Previous studies have demonstrated that PPAR-alpha activation stimulates keratinocyte differenti

43 In contrast to PPAR-alpha activation, PPAR-beta/deltain vivo did not di

44 nd anti-inflammatory effects exerted through PPAR-alpha activation.

45 AR-gamma activator (troglitazone), but not a PPAR-alpha activator (bezafibrate), strikingly diminishe

46 de that LTB(4) is a physiologically relevant PPAR-alpha activator in cells of the immune system.

47 ydroxy-octadecadienoic acids (HODEs), potent PPAR alpha activators.

48 de an added benefit to patients treated with PPAR-alpha activators for dyslipidemia.

49 PPAR-alpha activators, including fibrates, have been use

50 of fibroblasts with ciprofibrate or WY14643, PPAR-alpha activators, led to peroxisome proliferation a

51 Importantly, both PPAR-alpha activators, such as the fibric acid class of

52 oducts as candidate physiologically relevant PPAR-alpha activators.

53 on of antisteatotic versus anti-inflammatory PPAR-alpha activities in counteracting dietary-induced l

54 receptor alpha (PPAR-alpha)(3), and lowered PPAR-alpha activity increased Notum expression.

55 sion, and this suggests that ATGL influences PPAR-alpha activity independently of ligand-induced acti

56 In fact, PPAR-alpha agonism overstimulated mitochondrial TCA cycl

57 However, PPAR-alpha agonism was unable to normalize the effects o

58 which were presumably due to the concomitant PPAR-alpha agonism, lower respiratory quotient, and less

59 s that were similar to those elicited by the PPAR alpha agonist GW647.

60 This novel effect of the PPAR-alpha agonist could provide an added benefit to pat

61 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3

62 The PPAR-alpha agonist fenofibrate exhibited submicromolar a

63 Treatment of diabetic rats with a PPAR-alpha agonist induced hepatic fat oxidation via ket

64 The natural PPAR-alpha agonist oleoylethanolamide (OEA) and the synt

65 The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, wh

66 patocytes treated with dexamethasone and the PPAR-alpha agonist Wy14,643 induced PPARA and gluconeoge

67 We further demonstrate that treatment with a PPAR-alpha agonist, bezafibrate, is able to reverse the

68 The results indicate that OEA, acting as a PPAR-alpha agonist, facilitates memory consolidation thr

69 y studying the effects of a highly selective PPAR-alpha agonist, GW7647, on [(14)C]oleate metabolism

70 A highly selective and potent PPAR-alpha agonist, GW7647, was administered by mouth fo

71 amine the safety and efficacy of LY518674, a PPAR-alpha agonist.

72 isome proliferator-activated receptor-alpha (PPAR-alpha) agonist that exerts profound anti-inflammato

73 isome proliferator-activated receptor-alpha (PPAR-alpha) agonist WY-14,643 and the glucocorticoid dex

74 the present study, we demonstrate that these PPAR alpha agonists can increase the production of the T

75 These results suggest that PPAR alpha agonists such as gemfibrozil and fenofibrate,

76 The PPAR alpha agonists, gemfibrozil, ciprofibrate, and feno

77 The actions of OEA are mimicked by PPAR-alpha agonists and abolished in mutant mice lacking

78 Next generation PPAR-alpha agonists are more potent at high-density lipo

79 stress was evident in mice treated with the PPAR-alpha agonists coinciding with increased peroxisoma

80 drazine (PHZ)-induced stress erythropoiesis, PPAR-alpha agonists facilitate recovery of wild-type but

81 activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofibrate synergizes wi

82 t oleoylethanolamide (OEA) and the synthetic PPAR-alpha agonists GW7647 and Wy-14643 mimic these effe

83 Two distinct PPAR-alpha agonists have similar effects that are also c

84 Our discovery of the role of PPAR-alpha agonists in stimulating self-renewal of early

85 ly explain the sometimes equivocal effect of PPAR-alpha agonists on glycemia.

86 or cells suggests that the clinically tested PPAR-alpha agonists we used may improve the efficacy of

87 y chromatin sites with GR; when activated by PPAR-alpha agonists, additional PPAR-alpha is recruited

88 Dissociated PPAR-alpha agonists, selectively modulating PPAR-alpha t

89 We also show that PPAR-alpha alleviates anaemia in a mouse model of chroni

90 Interestingly, although PPAR alpha also exhibited high affinity for saturated lo

91 hat human airway smooth muscle cells express PPAR alpha and -gamma subtypes.

92 It interacts with PPAR alpha and acts as a coactivator by moderately stimu

93 PPAR delta agonist activity, improvement of PPAR alpha and gamma activity required the introduction

94 ha, although only in the genetic presence of PPAR alpha and with intact LPL hydrolysis.

95 Palmitoylethanolamide is an agonist of PPAR-alpha and an important regulator of pain and innate

96 ion downregulated mRNA expression of cardiac PPAR-alpha and FAO enzyme genes, decreased myocardial FA

97 ing effects, and safety profile, of the dual PPAR-alpha and PPAR-gamma agonist aleglitazar.

98 eNOS transgenic mice showed higher levels of PPAR-alpha and PPAR-gamma gene expression, elevated abun

99 ulates fat utilization through activation of PPAR-alpha and that this effect may contribute to its an

100 ss of fat, we infused adenovirus-leptin into PPAR alpha(-/-) and PPAR alpha(+/+) mice.

101 isome proliferator-activated receptor alpha (PPAR-alpha) and its target genes in mice with suppressed

102 isome proliferator-activated receptor-alpha (PPAR-alpha), and liver X receptor-alpha (LXRalpha).

103 isome proliferator-activated receptor-alpha (PPAR-alpha), and mammalian target of rapamycin (mTOR).

104 three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes.

105 diated through AMP-activated protein kinase, PPAR-alpha, and PPAR-gamma coactivator alpha, which in t

106 the DNA-binding activities of HNF-4alpha and PPAR-alpha, and reduced HNF-4alpha and PPAR-alpha target

107 c(+) ATMPhis expressing elevated PGC-1alpha, PPAR-alpha, and Ym-1 transcripts were selectively enrich

108 diet-induced hepatic insulin resistance in a PPAR-alpha-and diacylglycerol-dependent manner.

109 cell carcinoma, and support the concept that PPAR-alpha antagonism may be a potential therapeutic app

110 g-induced reinstatement were reversed by the PPAR-alpha antagonist, MK886.

111 , and were prevented by PPAR-alpha deletion, PPAR-alpha antagonists, and neurosteroid-enzyme inhibito

112 uorescence resonance energy transfer between PPAR alpha aromatic amino acids and bound corresponding

113 ce points to NAAA-regulated PEA signaling at PPAR-alpha as a critical control point for the induction

114 These results identify hepatic activation of PPAR-alpha as a mechanism underlying glucocorticoid-indu

115 opment of therapeutic strategies to activate PPAR-alpha as well as other PPARs may lead to new therap

116 (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other PPARs.

117 isome proliferator-activated receptor-alpha (PPAR-alpha) as the molecular target responsible for the

118 peroxisome proliferator-activated receptor (PPAR alpha) binds and is activated by a variety of synth

119 eroxyeicosatetrenoic acid (5-HPETE) activate PPAR-alpha but have no significant endogenous effect ind

120 rentiating effects persisted in mice lacking PPAR-alpha, but were decreased in mice deficient in reti

121 teatosis, and reactivation of HNF-4alpha and PPAR-alpha by increasing zinc availability and inhibitin

122 isome proliferator-activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofi

123 trol and corticosteroid-treated BFU-E cells, PPAR-alpha co-occupies many chromatin sites with GR; whe

124 known how putative endogenous ligands alter PPAR alpha conformation in order to affect transcription

125 for the pharmacological target of fibrates (PPAR-alpha), could be used to improve the selection of p

126 tissue repair in WT-DB mice, but not in the PPAR-alpha-/--DB mice.

127 re absent in endothelial cells isolated from PPAR alpha-deficient mice.

128 idized EPA had no such effect in LPS-treated PPAR alpha-deficient mice.

129 Studies in PPAR-alpha-deficient mice demonstrated that cardiomyocyt

130 No such effect was seen in PPAR-alpha-deficient mice.

131 enofibrate and GW7647, and were prevented by PPAR-alpha deletion, PPAR-alpha antagonists, and neurost

132 mimicked by exogenous PEA, and abolished by PPAR-alpha deletion.

133 Peroxisome proliferator-activated receptors (PPAR alpha, delta, gamma) are nuclear transcription fact

134 Three subfamilies, including PPAR-alpha, -delta, and -gamma, have been identified wit

135 The dual PPAR-alpha/delta agonist, GFT505, is a promising liver-t

136 inical proof-of-concept for combined FXR and PPAR-alpha/delta agonist-based therapies in NASH.

137 proliferator-activated receptor alpha/delta (PPAR-alpha/delta) agonist.

138 proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively.

139 This occurred via a PPAR alpha-dependent mechanism because oxidized EPA had

140 its protective effects are mediated by both PPAR-alpha-dependent and -independent mechanisms.

141 GW7647 and Wy-14643 mimic these effects in a PPAR-alpha-dependent manner.

142 By co-activating normal PPAR-alpha-dependent metabolism and abnormal PPAR-gamma

143 cement assays showed for the first time that PPAR alpha exhibits high affinity (1-14 nM K(d) values)

144 Indeed, whereas PPAR-alpha expression is first noted at gestational day

145 er kinase B1 but fails to normalize impaired PPAR-alpha expression or metabolic abnormalities associa

146 similar effects that are also contingent on PPAR-alpha expression, whereas potent and selective agon

147 isome proliferator-activated receptor-alpha (PPAR-alpha) expression, but its function in this tissue

148 In contrast to the similar affinities of PPAR alpha for fatty acyl-CoAs and unsaturated fatty aci

149 nd develop the hypothesis that modulation of PPAR-alpha function may be important for the regulation

150 caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were profiled by

151 e tested the hypothesis that saroglitazar, a PPAR alpha/gamma agonist would improve NASH in the diet-

152 s been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity

153 f 4-thiazolyl-phenyl derivatives with potent PPAR alpha/gamma/delta pan agonistic activity.

154 o improvement in insulin sensitivity through PPAR-alpha/gamma agonism, which remains unexplored.

155 Saroglitazar is a dual PPAR-alpha/gamma agonist approved for the treatment of d

156 substrate (VLDL >> LDL > HDL), PPAR isoform (PPAR alpha >> PPAR delta > PPAR gamma), and among fatty

157 igand binding domain activation in the order PPAR-alpha> >-gamma>-delta.

158 and wild-type mice, but not in mice in which PPAR-alpha had been deleted by homologous recombination

159 in nonhepatoma cells, whereas the RXR alpha-PPAR alpha heterodimer inhibits HNF4-dependent DHBV repl

160 isome proliferator-activated receptor alpha (PPAR alpha) heterodimer.

161 show that OEA induces satiety by activating PPAR-alpha, identify an unexpected role for this nuclear

162 ing or intracellular lipids by activation of PPAR-alpha improved insulin sensitivity and the diabetic

163 ear extracts that interacts with full-length PPAR alpha in the presence of ciprofibrate, a synthetic

164 ically distinct activators of PPAR-gamma and PPAR-alpha in a rat model of acute myocardial infarction

165 sion of wild-type or a DNA-binding-deficient PPAR-alpha in acute and chronic models of inflammation w

166 The role of PPAR-alpha in acute ischemia/reperfusion myocardial inju

167 dence supports a previously unknown role for PPAR-alpha in behavior regulation and suggests new strat

168 APAP toxicity, suggesting the importance of PPAR-alpha in diabetes-induced protection.

169 alpha (PPAR-alpha), we were unable to detect PPAR-alpha in either gemfibrozil-treated or untreated hu

170 uced both PPRE binding and nuclear levels of PPAR-alpha in fatty livers but increased those in lean l

171 but not isoform 2) as well as PPAR-beta and PPAR-alpha in freshly isolated cardiac myocytes and card

172 ha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.

173 The results suggest that PEA activation of PPAR-alpha in leukocytes serves as an early stop signal

174 Adenoviral reconstitution of PPAR-alpha in the livers of nondiabetic, normotensive, d

175 PEA selectively activates PPAR-alpha in vitro with an EC(50) value of 3.1 +/- 0.4

176 isome proliferator-activated receptor-alpha (PPAR-alpha) in microglial cells and isolating primary mi

177 peroxisome proliferator-activated receptors (PPAR-alpha) in the gut and recruiting local afferents of

178 isome proliferator-activated receptor-alpha (PPAR-alpha), in inhibiting the disease process of adopti

179 We demonstrate that two distinct ligands of PPAR-alpha (including clofibrate and WY 14643) also caus

180 ect the expression of genes independently of PPAR alpha, including the gene for the major inducible d

181 To determine the role of PPAR-alpha-independent mechanisms, the effect of GFT505

182 d inflammation, indicating a contribution of PPAR-alpha-independent mechanisms.

183 llar bilayers was delayed in animals lacking PPAR-alpha, indicating a transient functional defect.

184 activity and units indicates that clofibrate/PPAR alpha induced expression of retinal-reducing enzyme

185 Pharmacologically activated PPAR-alpha inhibited hepatic inflammatory responses and

186 ification of such a transcriptionally active PPAR alpha-interacting cofactor (PRIC) complex from rat

187 Activation of PPAR-alpha is a direct effect of intracellularly generat

188 activated by PPAR-alpha agonists, additional PPAR-alpha is recruited to GR-adjacent sites and presuma

189 isome proliferator-activated receptor alpha (PPAR-alpha) is a potential candidate for this key regula

190 isome proliferator-activated receptor-alpha (PPAR-alpha) is expressed in the heart and regulates gene

191 In the present study we used PPAR alpha knockout (KO) mice to determine whether this

192 ct of GFT505 was assessed in hApoE2 knock-in/PPAR-alpha knockout mice.

193 These findings suggest that activation of PPAR-alpha leads to increased cardiac fatty acid oxidati

194 a diet containing clofibrate (0.5%, w/w), a PPAR alpha ligand and peroxisome proliferator, increased

195 The PPAR-alpha ligand pirinixic acid (WY14643) functionally

196 on of PPAR-alpha receptors using a selective PPAR-alpha ligand results in cardiomyocyte necrosis in m

197 somal proliferator-activated receptor alpha (PPAR alpha) ligand, thus limiting inflammation.

198 We found that PPAR alpha ligands (clofibrate and WY14643) enhanced IL-

199 han saturated fatty acids, are high affinity PPAR alpha ligands provides a mechanism accounting for s

200 act on circulating lipoproteins to generate PPAR alpha ligands, providing a potentially important li

201 ed fatty acids may both represent endogenous PPAR alpha ligands.

202 ifferent types of lipids serve as endogenous PPAR-alpha ligands, with the relevant ligand varying bet

203 derived from ATGL-catalyzed lipolysis act as PPAR-alpha ligands.

204 We have attempted to analyze the role of PPAR-alpha-linked fatty acid metabolism in islet functio

205 We speculate that ligands of PPAR-gamma and PPAR-alpha may be useful in the therapy of conditions as

206 eptor (PPAR) gamma coactivator-1 (PGC-1) and PPAR-alpha may shift myocytes toward glycolytic metaboli

207 iptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative stress

208 of omega-3 fatty acids may be explained by a PPAR alpha-mediated anti-inflammatory effect of oxidized

209 s as a coactivator by moderately stimulating PPAR alpha-mediated transcription in transfected cells.

210 inhibitor of beta-oxidation, indicating that PPAR-alpha-mediated TAG depletion does not depend on rec

211 These findings indicate that PPAR-alpha mediates the anti-inflammatory effects of PEA

212 isome proliferator-activated receptor-alpha (PPAR-alpha) mediates these sequelae, mice deficient in l

213 hogenesis of cardiac dysfunction by crossing PPAR-alpha mice with transgenic mice with cardiac-specif

214 tion in skeletal muscle strips isolated from PPAR-alpha mice.

215 d adenovirus-leptin into PPAR alpha(-/-) and PPAR alpha(+/+) mice.

216 Thus, in PPAR alpha(-/-) mice, up-regulation of carnitine palmito

217 reduced in the liver of wild-type but not in PPAR alpha(-/-) mice.

218 liver of wild-type mice but was unchanged in PPAR alpha(-/-) mice.

219 n the wild-type mice but did not increase in PPAR alpha(-/-) mice.

220 ght declined 55% in wild-type but only 6% in PPAR alpha(-/-) mice; liver triacylglycerol fell 39% in

221 se rats and wild-type mice, but not in obese PPAR-alpha(-/-) mice.

222 dendrocytes isolated from both wild type and PPAR-alpha(-/-) mice.

223 In PPAR-alpha-/- mice we observed delayed stratum corneum f

224 l cells and isolating primary microglia from PPAR-alpha-/- mice, we have demonstrated that gemfibrozi

225 liferation and cell death appeared normal in PPAR-alpha-/- mice.

226 rformed on livers from non-DB and DB (WT and PPAR-alpha-/-) mice at 0 and 12 h after APAP.

227 In contrast, diabetes in PPAR knockout (PPAR-alpha-/-) mice failed to protect against APAP toxic

228 y pretreatment with an antagonist for either PPAR-alpha (MK886) or cannabinoid CB1 receptors (rimonab

229 +/- 0.4 microM and induces the expression of PPAR-alpha mRNA when applied topically to mouse skin.

230 ng dietary-induced liver fibrosis, we used a PPAR-alpha mutant lacking its DNA-binding-dependent acti

231 correlated with PEA-induced upregulation of PPAR-alpha, neurosteroidogenic enzyme expression, and no

232 To directly test this hypothesis, we fed PPAR-alpha null and wild-type mice for 2 weeks with isoc

233 fed safflower oil), whereas in contrast, in PPAR-alpha null mice failed to counteract hepatic insuli

234 In PPAR-alpha null mice fed the fish oil diet, safflower oi

235 hepatic insulin resistance (HGP, P = NS vs. PPAR-alpha null safflower oil-fed mice).

236 In the small intestine of wild-type but not PPAR-alpha-null mice, OEA regulates the expression of se

237 ection by GW7647 was completely abolished in PPAR-alpha-null mice.

238 The transrepression activity of PPAR-alpha on chronic liver inflammation is sufficient t

239 However, effects of PPAR-alpha on emotional behavior are poorly understood.

240 emphasized the potential for both actions of PPAR-alpha on insulin sensitivity that may be relayed sy

241 lta is severalfold more abundant than either PPAR alpha or PPAR gamma.

242 athic phenotype that occurred as a result of PPAR-alpha overexpression without affecting the metaboli

243 ight gain by activating the nuclear receptor PPAR-alpha (peroxisome proliferator-activated receptor a

244 These data relate retinoid metabolism, PPAR alpha, peroxisomes, and RRD, and are consistent wit

245 These results indicate that PPAR-alpha plays a physiologic role during fetal stratum

246 This study was designed to test whether PPAR-alpha plays a physiologic role in epidermal differe

247 isome proliferator-activated receptor alpha (PPAR alpha) plays a central role in the cell-specific pl

248 ave a subfamily of three different isoforms: PPAR alpha, PPAR gamma, and PPAR beta/delta.

249 ome proliferator-activated receptors (PPARs; PPAR-alpha, PPAR-delta, and PPAR-gamma) comprise a famil

250 peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-gamma and PPAR-delta) exemplify this co

251 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered

252 Treatments that activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combi

253 me proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

254 than currently available fibrates, and dual PPAR-alpha/PPAR-gamma agonists are under investigation t

255 The liganded PPAR alpha-PRIC complex enhanced transcription from a pe

256 Activation of PPAR-alpha protected the heart from reperfusion injury.

257 Robust induction of PPAR-alpha protein expression occurred during muscle cel

258 ntrast, hepatic levels of the PPAR-gamma and PPAR-alpha proteins were significantly lower in the Acc2

259 In contrast, activators of PPAR-alpha, RAR, RXR, or vitamin D receptor did not alte

260 Therefore, we evaluated the role that PPAR-alpha receptors play in the heart.

261 Our studies demonstrate that activation of PPAR-alpha receptors using a selective PPAR-alpha ligand

262 crosis is a consequence of the activation of PPAR-alpha receptors.

263 lpha-type peroxisome proliferator-activated (PPAR-alpha) receptors; (2) shifted nicotine self-adminis

264 We conclude that liganded PPAR alpha recruits a distinctive multiprotein complex f

265 Activation of PPAR-alpha reduces secretion of LTB(4) by stimulating de

266 Fasting increased expression of all PPAR-alpha -regulated genes in lean Zucker rat hearts, w

267 During fasting, a microbiota-dependent, Ppar alpha-regulated increase in hepatic ketogenesis occ

268 with the nuclear hormone receptors HNF-4 and PPAR-alpha, respectively.

269 fier of PGC-1alpha, a nuclear coactivator of PPAR-alpha responsive gene transcription.

270 ic models of inflammation were used to study PPAR-alpha's anti-inflammatory versus metabolic activiti

271 ective autophagy, restores SIRT1/FoxO3a/AMPK/PPAR-alpha signaling and rectifies metabolic abnormaliti

272 tion that 5-lipoxygenase stimulation induces PPAR-alpha signaling and that this results specifically

273 show that impaired SIRT1, FoxO3a, AMPK, and PPAR-alpha signaling are responsible for autophagy impai

274 This miR-27b-mediated repression of PPAR-alpha signaling represents a novel mechanism of HCV

275 iated by downregulation of SIRT1/FoxO3a/AMPK/PPAR-alpha signaling.

276 de an alternate mechanism that links ATGL to PPAR-alpha signaling.

277 isome proliferator-activated receptor alpha (PPAR-alpha) stimulation.

278 y acids), elicited conformational changes in PPAR alpha structure, a hallmark of ligand-activated nuc

279 These effects were mimicked by the PPAR-alpha synthetic agonists, fenofibrate and GW7647, a

280 P-1 activation, increasing expression of the PPAR alpha target gene I kappa B alpha, although only in

281 ein 3, two classical and robustly responsive PPAR alpha target genes, were similar between WT and KO

282 pe controls, despite comparable induction of PPAR alpha target genes.

283 r homogenates; and hepatic expression of key PPAR-alpha target (MCAD, mitochondrial HMG CoA synthase,

284 naling on SIRT1 activity, and PGC-1alpha and PPAR-alpha target gene expression independent of changes

285 o normalize the effects of ATGL knockdown on PPAR-alpha target gene expression, and this suggests tha

286 is required for the induction of PGC-1alpha/PPAR-alpha target genes and oxidative metabolism in resp

287 ice, OEA regulates the expression of several PPAR-alpha target genes: it initiates the transcription

288 a and PPAR-alpha, and reduced HNF-4alpha and PPAR-alpha target proteins.

289 Fatty acids bind and activate PPAR-alpha; therefore, it has been presumed that fatty a

290 We show here that MUT LDL activates PPAR alpha to an extent proportional to its LDL(-) conte

291 es were established that overexpressed human PPAR alpha to levels between 6- and 26-fold over normal

292 nk between lipoprotein metabolism and distal PPAR alpha transcriptional effects.

293 PPAR-alpha transgenic mice develop spontaneous cardiac h

294 PPAR-alpha agonists, selectively modulating PPAR-alpha transrepression activity, could thus be an op

295 PPAR-alpha was investigated further by immunohistochemis

296 isome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in g

297 isome proliferator-activated receptor-alpha (PPAR-alpha), we were unable to detect PPAR-alpha in eith

298 isome proliferator-activated receptor-alpha (PPAR-alpha) were examined as a model of diabetic cardiom

299 r-/-), with (Ppara+/+) or without (Ppara-/-) PPAR-alpha, were treated chronically with dexamethasone.

300 rug was equally effective in treating EAE in PPAR-alpha wild-type as well as knockout mice.